## Chlamydia pneumoniae Pneumonia — Clinical Recognition ### Clinical Presentation This patient exhibits classic features of C. pneumoniae CAP: - **Subacute onset** (2 weeks of progressive symptoms) - **Productive cough** with dyspnoea and low-grade fever - **Bilateral interstitial infiltrates** on CXR (reticular pattern) - **Negative sputum culture** (obligate intracellular pathogen; not culturable on routine media) - **Serological confirmation** — fourfold rise in CFT antibody titre (diagnostic gold standard) **Key Point:** C. pneumoniae is an obligate intracellular Gram-negative diplococcus responsible for 5–15% of community-acquired pneumonia cases, often in older adults and smokers [cite:Harrison 21e Ch 297]. ### Epidemiology & Risk Factors - **Age:** Peaks in older adults (>50 years) and children (<5 years) - **Smoking:** Major risk factor for severe disease - **Transmission:** Respiratory droplets; endemic worldwide - **Seasonality:** Autumn and winter in temperate regions ### Microbiological Features | Feature | C. pneumoniae | C. trachomatis | Mycoplasma | |---------|---------------|----------------|------------| | **Gram stain** | Gram-negative diplococcus | Gram-negative, small | Not visible | | **Culture** | Difficult; requires special media (HEp-2, HL cells) | Cell culture; NAAT preferred | Not culturable | | **Serology** | CFT, microimmunofluorescence | Microimmunofluorescence | CFT, ELISA | | **NAAT** | Available; sensitive | Gold standard | Available | | **CXR pattern** | Interstitial/lobar infiltrates | — | Interstitial (often unilateral) | **High-Yield:** Serological diagnosis (fourfold rise in CFT titre or single high titre ≥1:512) is the **diagnostic gold standard** for C. pneumoniae because culture is impractical in routine labs. ### Pathogenesis 1. **Inhalation** of respiratory droplets 2. **Attachment** to respiratory epithelium via outer membrane proteins 3. **Intracellular infection** → persistent infection possible 4. **Immune response** → antibody production (IgM early, IgG late) 5. **Tissue inflammation** → pneumonia, bronchitis, or asymptomatic carriage **Clinical Pearl:** C. pneumoniae can cause **persistent/chronic infection**, leading to recurrent respiratory symptoms and potential links to atherosclerosis and asthma exacerbation—a unique feature among the chlamydiae. ### Diagnostic Approach ```mermaid flowchart TD A[CAP with atypical features]:::outcome --> B{Sputum culture negative?}:::decision B -->|Yes| C[Consider atypical pathogens]:::action C --> D{CXR pattern?}:::decision D -->|Bilateral interstitial| E[C. pneumoniae or Mycoplasma]:::outcome D -->|Lobar consolidation| F[Legionella, viral]:::outcome E --> G{Serology or NAAT?}:::decision G -->|CFT fourfold rise| H[C. pneumoniae confirmed]:::action G -->|Cold agglutinins/CFT high| I[Mycoplasma considered]:::action ``` ### Treatment | Agent | Dose | Duration | Notes | |-------|------|----------|-------| | **Azithromycin** | 500 mg day 1, then 250 mg daily | 7–10 days | **First-line** | | **Doxycycline** | 100 mg twice daily | 7–10 days | Alternative; avoid in pregnancy | | **Fluoroquinolone** (levofloxacin, moxifloxacin) | Standard doses | 7–10 days | Effective; reserved for severe/resistant | | **Amoxicillin-clavulanate** | — | — | **NOT effective** (intracellular pathogen) | **Key Point:** β-lactams (penicillins, cephalosporins) are **ineffective** because C. pneumoniae lacks a cell wall and resides intracellularly. ### Why This Answer? - **Serological confirmation** (fourfold CFT rise) is pathognomonic for C. pneumoniae - **Negative sputum culture** rules out typical bacterial pathogens - **Bilateral interstitial infiltrates** and **subacute presentation** fit C. pneumoniae perfectly - **Smoking history** is a known risk factor for severe disease
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.